Globus Medical Grew Earnings 56% On 6% Revenue. The Robotics Line Went Backwards.

Let's get right to the number that will end up in every headline about this quarter. Globus Medical (GMED) reported second quarter non-GAAP earnings of $1.34 per share, up 55.8% from $0.86 a year earlier. Revenue grew 5.9% to $789.6 million. Management left full-year revenue guidance alone at $3.18 billion to $3.22 billion and lifted the adjusted EPS range to $4.95 to $5.05 from $4.70 to $4.80. Six percent revenue growth. Fifty-six percent earnings growth. That gap is the whole quarter, and most of the coverage aimed at retail investors will hand credit to robotics because that is the tidy version. I went through the filing line by line instead. The tidy version is wrong in a way that changes how you should size this position. The Technology Segment Shrank 26% Globus splits revenue into two buckets. Musculoskeletal Solutions, which is implants, instruments and biologics, came in at $763.5 million, up 7.5% year over year. Enabling Technologies, which is where the surgical robots, intraoperative imaging and navigation hardware sit, came in at $26.1 million against $35.2 million a year ago. That is a 25.8% decline, and the segment now accounts for 3.3% of total revenue. Read that twice. I did. I want to be careful here, because this is not news to the institutions. Sell side previews going back to the fourth quarter of last year were already modeling roughly a 28% year over year decline in that segment, so the professionals have been carrying it in their models for a while. What has not caught up is the popular framing of Globus as a surgical robotics company. If that is why you own it, you own a business where robotics contributes about three cents of every revenue dollar, and shrinking. The usual mental model for this kind of business is razor and blades: place the capital equipment in the hospital, then sell the implants that only work with it. This quarter the razors went backwards and the blades did all the work. Commentary on the earnings call pointed to a change in how the company takes enabling technology to market as one reason it held revenue guidance flat despite a top line beat, which suggests some of the decline is a deliberate model shift. Does that break the ecosystem thesis? Not on one quarter of data. But treat the pull-through argument as an inference and not a fact, because Globus does not disclose how many implant dollars follow a placed system, and without that number nobody outside the company can size the effect. So Where Did The Earnings Come From? Fair question, and the answer is unglamorous, which is usually a good sign.